We are live on ! Find out more
CCCC icon

C4 Therapeutics
CCCC

100 hedge funds and large institutions have $94.1M invested in C4 Therapeutics in 2023 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 36 increasing their positions, 35 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,467% more call options, than puts

Call options by funds: $154K | Put options by funds: $6K

3% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 35

6.45% less ownership

Funds ownership: 76.21% → 69.76% (-6.5%)

17% less funds holding

Funds holding: 120 → 100 (-20)

20% less capital invested

Capital invested by funds: $117M → $94.1M (-$23.3M)

56% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 36

Holders
100
Holders Change
-20
Holders Change %
-16.67%
% of All Funds
1.57%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
16
Increased
36
Reduced
35
Closed
36
Calls
$154K
Puts
$6K
Net Calls
+$148K
Net Calls Change
-$37K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$6.37M
2
WA
Wasatch Advisors
Utah
+$4.77M
3
NCM
Nantahala Capital Management
Connecticut
+$3.21M
4
ACM
Aquilo Capital Management
California
+$2.44M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$1.04M

Top Sellers

Rank Fund Capital Flow
1
ACH
ArrowMark Colorado Holdings
Colorado
-$19.5M
2
BlackRock
BlackRock
New York
-$5.18M
3
State Street
State Street
Massachusetts
-$1.99M
4
Geode Capital Management
Geode Capital Management
Massachusetts
-$1.29M
5
N
Nuveen
North Carolina
-$1.12M
Name Holding Trade Value Shares
Change 		Change in
Stake
Invesco
51
Invesco
Georgia
$154K -$43.5K -13,549 -20%
Fidelity Investments
52
Fidelity Investments
Massachusetts
$151K -$1.08K -335 -0.6%
Squarepoint
53
Squarepoint
New York
$143K -$179K -55,608 -52%
TD Asset Management
54
TD Asset Management
Ontario, Canada
$133K – – –
CIC
55
Cornercap Investment Counsel
Georgia
$132K – – –
UBS AM
56
UBS AM
Illinois
$123K – – –
PMEF
57
Point72 Middle East FZE
United Arab Emirates
$106K +$92.9K +28,904 +298%
SOW
58
State of Wyoming
Wyoming
$94.9K +$111K +34,494 New
PCM
59
Prelude Capital Management
New York
$93.5K +$109K +34,000 New
Bank of America
60
Bank of America
North Carolina
$92.6K -$57.3K -17,819 -35%
Barclays
61
Barclays
United Kingdom
$91.8K -$45K -13,995 -30%
GCM
62
Graham Capital Management
Connecticut
$90.7K +$106K +32,974 New
HSBC Holdings
63
HSBC Holdings
United Kingdom
$90.3K +$44.7K +13,893 +74%
OMC
64
Old Mission Capital
Illinois
$81.3K +$95K +29,548 New
CANY
65
Caxton Associates (New York)
New York
$73.5K -$39.2K -12,204 -31%
LCM
66
Laurion Capital Management
New York
$71.5K +$83.5K +25,983 New
American Century Companies
67
American Century Companies
Missouri
$65.9K +$29.9K +9,292 +63%
Bank of New York Mellon
68
Bank of New York Mellon
New York
$61.3K -$416K -129,276 -85%
PP
69
PDT Partners
New York
$58.9K -$184K -57,091 -73%
DS
70
DRW Securities
Illinois
$58K +$67.8K +21,100 New
CAM
71
Cresset Asset Management
Illinois
$55K +$28K +8,719 +77%
PFCS
72
Pale Fire Capital SE
Czech Republic
$52.8K +$61.7K +19,200 New
Citigroup
73
Citigroup
New York
$50.6K +$54.6K +16,983 +1,197%
JF
74
Jump Financial
Illinois
$49.3K +$57.6K +17,915 New
SFI
75
Susquehanna Fundamental Investments
Pennsylvania
$48.3K – – –
1 2
3
4 5

CCCC Hedge Fund Activity: Q2 2023 in Review

100 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in C4 Therapeutics (CCCC) for Q2 2023, worth a combined $94.1M — down 20% from $117M a quarter earlier.

Sellers outnumbered buyers: 36 funds closed out of CCCC and 16 opened new positions — a net loss of 20 holders — while 35 trimmed existing stakes and 36 added.

The largest buyer was Millennium Management, adding an estimated $6.37M. The largest seller was ArrowMark Colorado Holdings, cutting an estimated $19.5M.

  • 100 institutional investors held C4 Therapeutics (CCCC) as of Q2 2023, down from 120 in Q1 2023.
  • Funds reported $94.1M of C4 Therapeutics stock for Q2 2023, down 20% quarter-over-quarter.
  • 16 funds opened new C4 Therapeutics positions in Q2 2023 and 36 closed out, a net change of -20 holders.
  • The largest C4 Therapeutics buyer in Q2 2023 was Millennium Management, an estimated $6.37M added.
  • The largest C4 Therapeutics seller in Q2 2023 was ArrowMark Colorado Holdings, an estimated $19.5M sold.

Based on aggregated 13F filings for Q2 2023.